Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma

Cancer

Volumn 117, Issue 16, 2011, Pages 3763-3773

  Liu, Dan ^a   Huang, Yi ^b   Chen, Bojiang ^a   Zeng, Jing ^a   Guo, Na ^a   Zhang, Shangfu ^a   Liu, Lunxu ^a   Xu, Hong ^a   Mo, Xianming ^a   Li, Weimin ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

activated kinases; mammalian target of rapamycin pathway; nonsmall cell lung carcinoma; prognosis; protein expression profiles

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; S6 KINASE;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 80051479542     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25959     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 2004; 10: 6779-6788. (Pubitemid 39383026)
3. Bjornsti MA, Houghton PJ,. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4: 335-348. (Pubitemid 38579480)
4. Borders EB, Bivona C, Medina PJ,. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm. 2010; 67: 2095-2106.
5. Janus A, Robak T, Smolewski P,. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett. 2005; 10: 479-498. (Pubitemid 41564520)
6. Jendrossek V, Henkel M, Hennenlotter J, et al. Analysis of complex protein kinase B signalling pathways in human prostate cancer samples. BJU Int. 2008; 102: 371-382. (Pubitemid 352019202)
7. Woo HG, Park ES, Lee JS, et al. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res. 2009; 69: 4059-4066.
8. Restuccia DF, Hemmings BA,. From man to mouse and back again: advances in defining tumor AKTivities in vivo. Dis Model Mech. 2010; 3: 705-720.
9. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N,. mTOR, translation initiation and cancer. Oncogene. 2006; 25: 6416-6422. (Pubitemid 44582285)
10. Gomez-Martin C, Rubio-Viqueira B, Hidalgo M,. Current status of mammalian target of rapamycin inhibitors in lung cancer. Clin Lung Cancer. 2005; 7 (suppl 1): S13-S18.
11. Zhou X, Lin DS, Zheng F, Sutton MA, Wang H,. Intracellular calcium and calmodulin link brain-derived neurotrophic factor to p70S6 kinase phosphorylation and dendritic protein synthesis. J Neurosci Res. 2010; 88: 1420-1432.
12. Byfield MP, Murray JT, Backer JM,. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem. 2005; 280: 33076-33082. (Pubitemid 41368357)
13. Deldicque L, Atherton P, Patel R, et al. Decrease in Akt/PKB signalling in human skeletal muscle by resistance exercise. Eur J Appl Physiol. 2008; 104: 57-65.
14. Wangpaichitr M, Wu C, You M, et al. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol. 2008; 591: 124-127.
15. Johnson BE, Jackman D, Janne PA,. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res. 2007; 13 (15 pt 2): s4628-s4631.
16. Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T,. A phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 2010; 40: 732-738.
17. Memmott RM, Dennis PA,. The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res. 2009; 16: 4-10.
18. Pal SK, Figlin RA, Reckamp KL,. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008; 9: 340-345.
19. Wan X, Helman LJ,. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007; 12: 1007-1018. (Pubitemid 47359144)
20. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC,. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
21. International Union Against Cancer. TNM Classification of Malignant Tumors. 6th ed. New York, NY: Wiley & Sons; 2002.
22. The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer. Clin Oncol (R Coll Radiol). 1999; 11: S1-S53.
23. Tang JM, He QY, Guo RX, Chang XJ,. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006; 51: 181-191.
24. Yoshizawa A, Fukuoka J, Shimizu S, et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 2010; 16: 240-248.
25. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M,. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004; 10: 8421-8425. (Pubitemid 40053405)
26. Dubrovska A, Elliott J, Salamone RJ, et al. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin Cancer Res. 2010; 16: 5692-5702.
27. Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 2010; 210: 767-778.
28. Dhillon T, Mauri FA, Bellezza G, et al. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 2010; 5: 314-319.
29. Anagnostou VK, Bepler G, Syrigos KN, et al. High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res. 2009; 15: 4157-4164.
30. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL,. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia. 2005; 7: 1-6. (Pubitemid 40209465)
31. Gridelli C, Maione P, Rossi A,. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 2008; 13: 139-147. (Pubitemid 351342577)
32. Bayascas JR,. PDK1: the major transducer of PI 3-kinase actions. Curr Top Microbiol Immunol. 2011; 346: 9-29.
33. Sato S, Fujita N, Tsuruo T,. Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3. J Biol Chem. 2002; 277: 39360-39367. (Pubitemid 35190909)
34. Balendran A, Casamayor A, Deak M, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol. 1999; 9: 393-404. (Pubitemid 29205782)
35. Chan TO, Tsichlis PN,. PDK2: a complex tail in 1 Akt. Sci STKE. 2001; 2001: pe1.
36. Williams MR, Arthur JS, Balendran A, et al. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol. 2000; 10: 439-448. (Pubitemid 30247331)
37. Cicenas J,. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers. 2008; 23: 1-9. (Pubitemid 351715539)
38. Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of 2 phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol. 2006; 24: 306-314. (Pubitemid 46622059)
39. Salot S, Gude R,. MTA1 Aids the AKT pathway by inhibiting expression of a key regulator, PTEN. J Cancer Sci Ther. 2010; 2: 114-119.
40. Tsurutani J, Steinberg SM, Ballas M, et al. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer. 2007; 55: 115-121. (Pubitemid 46038882)
41. Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA,. Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer. 2005; 92: 2266-2277. (Pubitemid 40966266)
42. Hagner PR, Schneider A, Gartenhaus RB,. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood. 2010; 115: 2127-2135.
43. Ferrari S, Bannwarth W, Morley SJ, Totty NF, Thomas G,. Activation of p70s6k is associated with phosphorylation of 4 clustered sites displaying Ser/Thr-Pro motifs. Proc Natl Acad Sci U S A. 1992; 89: 7282-7286.
44. Thomas G,. The S6 kinase signaling pathway in the control of development and growth. Biol Res. 2002; 35: 305-313. (Pubitemid 35189803)
45. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA,. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 2007; 13 (2 pt 2): 703s-708s.
46. Lehman JA, Calvo V, Gomez-Cambronero J,. Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, m-TOR-related THR389 kinase. J Biol Chem. 2003; 278: 28130-28138. (Pubitemid 36900011)